POS0721 ARE ANTIMALARIALS SAFE FOR THE HEART OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS? ANALYSIS OF FACTORS ASSOCIATED WITH THE DEVELOPMENT OF HEART FAILURE IN PATIENTS IN THE SPANISH SOCIETY OF RHEUMATOLOGY LUPUS REGISTRY (RELESSER)

Autor: José M. Pego-Reigosa, E. Tomero Muriel, E. Uriarte Isacelaya, Elia Valls-Pascual, Elena Aurrecoechea, Iñigo Rúa-Figueroa, I. Jiménez-Moleón, J.A. Narváez, N. Lozano Rivas, Raúl Menor-Almagro, Eduardo Salas, Miriam Moreno, Alina Boteanu, T. R. Vazquez Rodriguez, Lorena Expósito, V. Quevedo Vila, C. A. Montilla-Morales, Antonio Fernández-Nebro, C. Mouriño, Jaime Calvo-Alén, M. Freire González, Gemma Bonilla, J.A. Bernal, Cristina Bohórquez, Tatiana Cobo-Ibáñez, Arantxa Mas, ML Velloso Feijoo, J. A. Hernandez Beriain, Roman Blanco, O. Ibarguengoitia, D. Rua-Figueroa, E. Salgado Perez, J.L. Andreu Sánchez, N. Pérez-Veiga, A. Pecondon, C. Sanguesa, María Galindo-Izquierdo, F. J. Toyos Sáenz de Miera, A. M. Anzola Alfaro, N. Del-Val
Rok vydání: 2021
Předmět:
Zdroj: Annals of the Rheumatic Diseases. 80:610-611
ISSN: 1468-2060
0003-4967
DOI: 10.1136/annrheumdis-2021-eular.1208
Popis: Background:Factors associated with the development of chronic heart failure (CHF) in systemic lupus erythematosus (SLE) have received little attention. On the other hand, recent data from the use of hydroxychloroquine in the treatment of SARS-CoV-2 infection during the COVID19 pandemic have cast some doubts on its cardiological safety.Objectives:To identify factors associated to CHF in SLE.Methods:Retrospective cross-sectional study, including all patients with SLE (≥4 ACR-1997 criteria) recruited in RELESSER registry. The objectives and methodology of the registry have been described previously (1). CHF was defined according to the Charlson index item. Patients with CHF before diagnosis of SLE were excluded. Cumulative damage was measured with the SLICC/ACR index, excluding cardiovascular (CV) items (mSDI). Multivariate analysis exploring factors associated with CHF was carried out.Results:117 patients (3% of the entire cohort) with SLE and CHF and 3,506 controls with SLE without CHF were included. 90% were women. Disease duration: mean (SD), 120.2 (87.7) months. CHF appeared after a median (P25-P75) of 9.40 (4.2-18.3) years from SLE diagnosis. Patients with CHF were older (59.8 ± 18.2 vs. 46.2 ± 4.3). In the bivariate analysis, the association of CHF with greater severity [Katz severity index: median (IQR): 4 (3-5) vs. 2 (1-3)], damage [mSDI: 3 (2-4) vs 0 (0-1)], comorbidity [modified Charlson- excluding CV items: 4 (3-6) vs 1(1-3)] and both CV (37.5% vs 6.7%) and overall mortality (43.2% vs 4.7%) (pTable 1.Congestive heart failure associated factors (multivariable analysis)Odds Ratio95% CIP-valueSex (female)0.460.25 - 0.880.0147Ischaemic cardiopathy7.964.01 - 15.48Cardiac arrhythmia7.384.00 - 13.42Pulmonary hypertension3.711.84 - 7.250.0002Cardiac valvulopathy6.333.41 - 11.62Hospitalization (due to SLE)3.741.81 - 8.650.0008Calcium or vitamin D5.292.07 - 16.860.0015Antimalarials0.280.17 - 0.45mSDI *1.291.16 - 1.44*mSDI = modified SLICC/ACR damage index (without cardiovascular items)Conclusion:- CHF is a rather late complication of SLE.- Patients with SLE and CHF have more severe SLE, with greater refractoriness to SLE treatments and higher overall mortality.- Treatment with antimalarials, as routinely used in SLE patients, is not only safe to heart, but even appears to have a cardioprotective effect.References:[1]Rúa-Figueroa I, López-Longo FJ, Calvo-Alén J, et al. National registry of patients with systemic lupus erythematosus of the Spanish Society of Rheumatology: objectives and methodology. Reumatol Clin. 2014;10(1):17-24.Acknowledgements:Research Unit of Spanish Society of RheumatologyDisclosure of Interests:None declared
Databáze: OpenAIRE
Externí odkaz: